World Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Wellness Times.

Press releases published on November 9, 2026

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
WILDx Mastermind and Media Day Brings Speakers Together for Branding, Media Training and National Exposure
LULU Stock Alert: Lululemon Stock Plummets 17% after Growth Issues Disclosed – Contact BFA Law about the Pending Securities Fraud Class Action
Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer  
Epitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancé  
VapoLung Introduces VapoLung Spray, a Five-Ingredient Oral Dietary Supplement for Daily Respiratory Wellness
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
Valneva annonce des résultats positifs de phase 2 pour son candidat vaccin tétravalent contre la shigellose S4V2
Essential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiency
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
Ahead of Black Friday 2026, QuasarMD Spotlights Its Full-Body Red Light Therapy Mat for At-Home Wellness
Fangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care Innovation
InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

World Wellness Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.